目的验证利福喷丁治疗肺结核病的疗效。
Objective To test the efficacy of rifapention on treating patients with pulmonary tuberculosis.
有些用标准DOTS疗法，每日的卫非特，而其他的用利福喷丁替代利福平。
Some were treated with the standard DOTS regimen, daily Rifater, while others took rifapentine in place of rifampin.
结果：抗结核药用药金额年平均增长率为10.65％，百生肼、利福喷丁用量上升。
The annual increase rate of sum of money of drugs was 10. 65% in average. The consumption of pasiniazide and rifapentin was increased.
服用利福喷丁和异烟肼在10周后显示清除了细菌，但是至少10%恨可能复发除非持续治疗一周。
Those treated with rifapentine and isoniazid also tested clear of the bacterium by 10 weeks, but were at least 10 percent more likely to relapse unless treatment persisted for another month.
方法对HBVM阳性和阴性肺结核病人分别用利福喷丁和利福平治疗，观察治疗前后肝功能损害情况。
Method in HBVM positive group and negative group treated with rifapentine or rifampicin, liver function injury were observed before and after treatment.
药物治疗10周后，服用利福喷丁和莫西沙星的小鼠对肺结核显示阴性结果，三个月之后显示同样的结果。
After 10 weeks of drug therapy, mice taking rifapentine and moxifloxacin tested negative for active TB and remained so when retested three months later.
利福喷丁是1998年由美国FDA批准的治疗广布的，药物敏感性的肺结核药物，最初是作为不太累赘的，一周一次的药剂。
Rifapentine, approved by the U. S. Food and drug Administration in 1998 for treating widespread, drug-susceptible TB, was initially developed as a less cumbersome, once-weekly tablet.
方法测定脱乙酰基利福喷丁抗人型、牛型、草型结核杆菌的最低抑菌浓度（MIC10 0 ）及小鼠半数动物存活时间（ST50 ）。
Methods The MIC100 values of 25-O-desacetylrifapentine against M. tuberculosis, M. bovis and M. phlie, and the values of half survival time (ST50) for the mice were detected.
方法测定脱乙酰基利福喷丁抗人型、牛型、草型结核杆菌的最低抑菌浓度（MIC10 0 ）及小鼠半数动物存活时间（ST50 ）。
Methods The MIC100 values of 25-O-desacetylrifapentine against M. tuberculosis, M. bovis and M. phlie, and the values of half survival time (ST50) for the mice were detected.
应用推荐